Mark Plavsic Biography and Net Worth

CTO of Aura Biosciences

Mark Plavsic is the Chief Technology Officer at Aura. Before joining Aura, Mark served as Chief Technology Officer at Fate Therapeutics, a clinical-stage biopharmaceutical company, and was previously Chief Technical Officer at Lysogene, a late-stage gene therapy company. Dr. Plavsic also spent over 10 years at Sanofi Genzyme in Technical Operations, where he was head of product safety and global manufacturing process improvement, and in Technology Development & Manufacturing, where he was head of gene therapy development. Before joining Sanofi Genzyme, Dr. Plavsic held various technical leadership positions with AstraZeneca, Q-One Biotech, and Life Technologies. Mark brings 30 years of global biopharmaceutical experience including end-to-end technical operations in the United States, Europe, and Australasia and successful translation and scale-up of complex biologics from preclinical development through commercial launch and distribution. Dr. Plavsic received his Ph.D. in Virology and Immunology and his DVM from the University of Belgrade, and is board certified in Microbiology, subspeciality Virology from the American College of Veterinary Microbiologists, and Regulatory Affairs Certification (RAC) credentialed.

What is Mark Plavsic's net worth?: The estimated net worth of Mark Plavsic is at least $1.27 million as of October 16th, 2025. Dr. Plavsic owns 197,287 shares of Aura Biosciences stock worth more than $1,272,501 as of December 5th. This net worth estimate does not reflect any other assets that Dr. Plavsic may own. Learn More about Mark Plavsic's net worth.
How do I contact Mark Plavsic?: The corporate mailing address for Dr. Plavsic and other Aura Biosciences executives is , , . Aura Biosciences can also be reached via phone at 617-500-8864 and via email at [email protected]. Learn More on Mark Plavsic's contact information.
Has Mark Plavsic been buying or selling shares of Aura Biosciences?: In the last ninety days, Mark Plavsic has sold $77,273.15 in Aura Biosciences stock. Most recently, Mark Plavsic sold 12,169 shares of the business's stock in a transaction on Thursday, October 16th. The shares were sold at an average price of $6.35, for a transaction totalling $77,273.15. Following the completion of the sale, the chief technology officer now directly owns 197,287 shares of the company's stock, valued at $1,252,772.45. Learn More on Mark Plavsic's trading history.
Who are Aura Biosciences' active insiders?: Aura Biosciences' insider roster includes Elisabet de los Pinos (Insider), Amy Elazzouzi (SVP), Anthony Gibney (Insider), Janet Hopkins (Chief Medical Officer and President of Research & Development), David Johnson (Director), Conor Kilroy (Insider), and Mark Plavsic (CTO). Learn More on Aura Biosciences' active insiders.
Are insiders buying or selling shares of Aura Biosciences?: In the last twelve months, Aura Biosciences insiders bought shares 2 times. They purchased a total of 70,000 shares worth more than $343,000.00. In the last twelve months, insiders at the sold shares 13 times. They sold a total of 79,568 shares worth more than $514,201.11. The most recent insider tranaction occured on November, 17th when insider Janet Jill Hopkins sold 17,109 shares worth more than $92,730.78. Insiders at Aura Biosciences own 6.3% of the company. Learn More about insider trades at Aura Biosciences.
Information on this page was last updated on 11/17/2025.

Mark Plavsic Insider Trading History at Aura Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/16/2025	Sell	12,169	$6.35	$77,273.15	197,287
2/18/2025	Sell	2,151	$7.75	$16,670.25	209,456
10/16/2024	Sell	7,383	$9.85	$72,722.55	121,132

Mark Plavsic Buying and Selling Activity at Aura Biosciences

Aura Biosciences Company Overview

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $6.45

$6.21

$6.53

50 Day Range

MA: $5.92

$5.35

$6.61

2 Week Range

Now: $6.45

$4.34

$9.14

Volume

117,755 shs

Average Volume

200,153 shs

Market Capitalization

$409.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44